What this trial means for you
This study is recruiting now at 23 US sites. It's studying NNC0662-0419, Semaglutide, Placebo for diabetes mellitus, type 2.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion criteria * Male or female (sex at birth). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening. * Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline). Exclusion criteria * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.
Study sites by state
California
- First Valley Medical Group, Lancaster · Recruiting now
- Torrance Clinical Research Institute, Inc., Lomita · Recruiting now
- Ark Clinical Research, Long Beach · Recruiting now
- Pacific Clinical Studies, Los Alamitos · Recruiting now
- Wetlin Research Associates, Inc., San Diego · Recruiting now
- Diablo Clinical Research, Inc., Walnut Creek · Recruiting now
Florida
- Encore Medical Research LLC, Hollywood · Recruiting now
- Bioclinical Research Alliance, Miami · Recruiting now
- South Broward Research LLC, Miramar · Recruiting now
- West Orange Endocrinology, Ocoee · Opening soon
- Encore Medical Research of Weston, Weston · Recruiting now
Idaho
- Elite Clinical Trials, Blackfoot · Recruiting now
Illinois
- Cedar-Crosse Research Center, Chicago · Recruiting now
Massachusetts
- Brigham & Women's Hospital, Boston · Opening soon
Missouri
- Headlands Research, Springfield · Recruiting now
North Carolina
- PharmQuest, Greensboro · Recruiting now
- Piedmont Healthcare Statesville, Statesville · Recruiting now
Ohio
- Providence Center for Clinical Research, Dayton · Recruiting now
Tennessee
- CNS Healthcare, Memphis · Recruiting now
Texas
- University of Texas Southwestern Medical Center, Dallas · Recruiting now
- JCCT- Juno NW Houston, Houston · Recruiting now
- Consano Clinical Research, LLC, Shavano Park · Recruiting now
West Virginia
- Frontier Clinical Research - Kingwood, Kingwood · Opening soon
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.